Lonza Prices CHF 350 Million Dual Tranche Straight Bonds

November 15,2011 Basel, Switzerland

Lonza Swiss Finance Ltd, a wholly-owned company of Lonza Group Ltd, Basel (“Lonza”), announces the pricing of its dual tranche CHF 350 million straight bonds. The bonds have a maturity of 4 years, respectively 7 years with coupons of 2.25% and 3.125%. The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the SIX Swiss Exchange. The proceeds of the bonds will be used for refinancing part of the bridge loans Lonza has been borrowing from a bank syndicate to acquire Arch Chemicals Inc.

 

Key data:

Issue size 4 year bond: CHF 210 million
Expected payment date: 07 December 2011
Maturity: 07 December 2015 (4 years)
Issue price: 100.47 percent
Redemption price: 100 percent
Coupon: 2.25 percent p.a.
Joint Lead Managers: Credit-Suisse and UBS Investment Bank
Co-Lead Managers: Basler Kantonalbank
Zürcher Kantonalbank

Issue size 7 year bond: CHF 140 million
Expected payment date: 07 December 2011
Maturity: 07 December 2018 (7 years)
Issue price: 100.56 percent
Redemption price: 100 percent
Coupon: 3.125 percent p.a.
Joint Lead Managers: Credit-Suisse and UBS Investment Bank
Co-Lead Managers: Basler Kantonalbank
Zürcher Kantonalbank

 

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers’ needs from research to final product manufacture. It is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza is not subject to the SGX-ST’s continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2010, the company had sales of CHF 2.680 billion. Further information can be found at www.lonza.com.

 

Further information

Lonza Group Ltd
Head of Corporate Communications
Dominik Wener
Tel +41 61 316 8798
Fax +41 61 316 9798
dominik.werner@lonza.com

 

Lonza Group Ltd
Investor Relations
Dirk Oehlers
Tel +41 61 316 8540
Fax +41 61 316 9540
dirk.oehlers@lonza.com

 

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 201 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com

Browse All News
Bg